41 | PROSPECTIVE VALIDATION OF END OF TREATMENT ctDNA‐MRD BY PhasED‐Seq IN DLBCL PATIENTS FROM A NATIONAL HOVON TRIAL.
Saved in:
| Title: | 41 | PROSPECTIVE VALIDATION OF END OF TREATMENT ctDNA‐MRD BY PhasED‐Seq IN DLBCL PATIENTS FROM A NATIONAL HOVON TRIAL. |
|---|---|
| Authors: | Chamuleau, M. E., Wang, S., Nijland, M., Strobbe, L., Oosterveld, M., Boersma, R., Koene, H., Klerk, C. P., de Jongh, E., Koster, A., Pruijt, H., van der Poel, M., van Werkhoven, E., Dinmohamed, A., van den Bosch, T., Sworder, B. J., Close, S., Brown, K., Meek, S., Alizadeh, A. A., et al |
| Source: | Hematological oncology 2025 Supplement; Vol. 43. |
| Journal Info: | Publisher: Wiley-Blackwell ISSN: 0278-0232 |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1099-1069 |
|---|---|
| DOI: | 10.1002/hon.70093_41 |
